BenevolentAI, one of the companies vying to improve healthcare through artificial intelligence analysis, says it has raised $115 million to accelerate its drive to discover new drugs by studying disease processes at the molecular level. The London-based company, which has offices in New York and Belgium, says the new capital brings its current valuation to […]